Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Mar 15, 2023 4:43pm
259 Views
Post# 35341013

RE:RE:RE:RE:About the addition of up to 9 CSS ...

RE:RE:RE:RE:About the addition of up to 9 CSS ...Hi CancerSlayer - Thanks for that. It's a new area for me. I'm not sure if this ROS resistance applies to pdt or not because of the violence of the reaction when the PS is exposed to light and the immediacy of damage to surrounding tissue.

"PDT uses a PS molecule as a prodrug that under light irradiation generates an intense blast of reactive oxygen species (ROS) such as superoxides (O2−), hydroxyl radicals (HO−), and/or singlet oxygen 1O2, which eventually cause cytotoxic damage to biomolecules adjacent to the PS."

"TLD1433 is known to generate reactive oxygen species (ROS) with high quantum efficacy in many cancer cell lines."

TLD1433 Photosensitizer Inhibits Conjunctival Melanoma Cells in Zebrafish Ectopic and Orthotopic Tumour Models


<< Previous
Bullboard Posts
Next >>